



Fact Sheet

About the Cleveland Cord Blood Center (CCBC)

One of only eight FDA licensed cord blood centers in the U.S., the Cleveland Cord Blood Center (CCBC) collects, processes, stores and distributes stem-cell rich umbilical cord blood for transplantation in patients with life-threatening disorders such as leukemia, lymphoma and immune system disorders. The Cleveland Cord Blood Center's commitment to a diverse inventory of cord blood helps enhance the availability of a match for life-saving treatments, particularly for minority groups and patients of mixed heritage. In addition, CCBC cord blood units are used by our researchers as well as others around the country to explore and advance umbilical cord blood's untapped potential as a life-saving cell therapy treatment. The Cleveland Cord Blood Center was founded by Mary J. Laughlin, M.D., who performed one of the world's first successful umbilical cord blood stem cell transplants on an adult leukemia patient in 1995.

Locations

Headquarters: 25001 Emery Road, Suite 150, Cleveland, Ohio 44128

Research and development laboratory: The Global Cardiovascular Innovation Center located in Cleveland

Hospital collection sites: in Cleveland Ohio, - Hillcrest Hospital and Fairview Hospital; in Atlanta, Georgia - Emory Midtown Hospital and Piedmont Atlanta Hospital; in San Leandro, California- the Kaiser Permanente San Leandro Medical Center; in Berkeley, California- the Alta Bates Sutter Medical Center

Website

clevelandcordblood.org

What are cord blood stem cells?

Cord blood-derived stem cells are collected after delivery from umbilical cords and placentas of full-term babies. These cells are a source of blood cell-forming (hematopoietic) stem cells with the potential to treat patients with life-threatening blood disorders.

FDA approval for CLEVECORD™

On September 1, 2016, the CCBC received a biologics license from the U.S. Food and Drug Administration (FDA) for CLEVECORD, a stem cell product derived from umbilical cord blood for use in stem cell transplants. The FDA approval of CLEVECORD reflects the organization's ability to meet the highest quality standards in the industry for distribution of cord blood products to transplant centers throughout the U.S. and around the world.

CCBC research and development

Located at the Global Cardiovascular Innovation Center in Cleveland, CCBC researchers are exploring and advancing umbilical cord blood's untapped potential as a cell therapy treatment for diseases ranging from wound healing and Parkinson's disease to autoimmune inflammation conditions such as Type 1 diabetes and diabetic retinopathy. In addition, CCBC cord blood units are used by scientists and other collaborators in exploration of the virtually unlimited lifesaving and life-giving possibilities that cord blood holds.

Cord blood donations

Cord blood is an ideal source of stem cells. The collection procedure does not interfere with the normal birthing process. No longer discarded as medical waste, the cells are collected at childbirth (after delivery, at minimal risk to the mother or baby) and then are meticulously tested, processed, frozen and stored. Once approved for clinical use, the unit is listed on an international registry which is accessible by doctors worldwide. In addition, CCBC cord blood units are being used by our scientists and other research organizations in the exploration of the virtually unlimited lifesaving and life-giving possibilities.

Cellular therapy initiatives

CCBC has formed two social enterprise subsidiaries, Cleveland Cell Therapy Incubator (CCTI) and Advanced Immune Cellular Therapeutics (AICT). These new entities expand our operations from collection and research to initial proof of concept to intellectual property and eventually to new products introduced into the marketplace that provide cellular therapy treatments.

The organization's new strategic outlook drives our focus on creating a cohesive, innovative, research-driven organization recognized for cellular therapy advancement, patient care, leadership, technology and collaboration.

Media inquiries

Contacts: Marcie Finney, CCBC
 216-896-0360, mfinney@clevelandcordblood.org